Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes
of death in the industrialized countries. In the setting of acute coronary syndromes (both ST – segment or non
ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development.
Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated
platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting
atherothrombotic disease. Recent patent relates to the methods and devices for treating atherosclerosis and to prevent
in-stent restenosis or thrombosis. Because of the importance of platelets involvement in the initiation and propagation
of thrombosis, antiplatelet drugs have a source of research; in the recent past, new antiplatelet drugs (such as ticagrelor)
have been studied and placed in the routine therapy. The aim of this paper is to summarize the pharmacological properties
and the clinical characteristics of ticagrelor.
Keywords: Acute coronary syndromes, atherosclerosis, antiplatelet therapy, bleeding, thrombosys.
Rights & PermissionsPrintExport